BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33775836)

  • 1. Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
    Asaba KN; Adachi Y; Tokumaru K; Watanabe A; Goto Y; Aoki T
    Bioorg Med Chem Lett; 2021 Jun; 41():127996. PubMed ID: 33775836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.
    Schiesser S; Hajek P; Pople HE; Käck H; Öster L; Cox RJ
    Eur J Med Chem; 2022 Jan; 227():113925. PubMed ID: 34742013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-based covalent inhibitors of MALT1 paracaspase.
    Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.
    Lu T; Connolly PJ; Philippar U; Sun W; Cummings MD; Barbay K; Gys L; Van Nuffel L; Austin N; Bekkers M; Shen F; Cai A; Attar R; Meerpoel L; Edwards J
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126743. PubMed ID: 31678006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Potent, Highly Selective, and
    Pissot Soldermann C; Simic O; Renatus M; Erbel P; Melkko S; Wartmann M; Bigaud M; Weiss A; McSheehy P; Endres R; Santos P; Blank J; Schuffenhauer A; Bold G; Buschmann N; Zoller T; Altmann E; Manley PW; Dix I; Buchdunger E; Scesa J; Quancard J; Schlapbach A; Bornancin F; Radimerski T; Régnier CH
    J Med Chem; 2020 Dec; 63(23):14576-14593. PubMed ID: 33252239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
    Schlapbach A; Revesz L; Pissot Soldermann C; Zoller T; Régnier CH; Bornancin F; Radimerski T; Blank J; Schuffenhauer A; Renatus M; Erbel P; Melkko S; Heng R; Simic O; Endres R; Wartmann M; Quancard J
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2153-2158. PubMed ID: 29759726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
    Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
    PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
    Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
    Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
    Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
    Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
    Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
    J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A patent review of MALT1 inhibitors (2013-present).
    Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
    Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosa-associated lymphoid tissue lymphoma translocation 1 as a novel therapeutic target for rheumatoid arthritis.
    Lee CH; Bae SJ; Kim M
    Sci Rep; 2017 Sep; 7(1):11889. PubMed ID: 28928392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.
    Bardet M; Unterreiner A; Malinverni C; Lafossas F; Vedrine C; Boesch D; Kolb Y; Kaiser D; Glück A; Schneider MA; Katopodis A; Renatus M; Simic O; Schlapbach A; Quancard J; Régnier CH; Bold G; Pissot-Soldermann C; Carballido JM; Kovarik J; Calzascia T; Bornancin F
    Immunol Cell Biol; 2018 Jan; 96(1):81-99. PubMed ID: 29359407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors.
    Wu G; Wang H; Zhou W; Zeng B; Mo W; Zhu K; Liu R; Zhou J; Chen C; Chen H
    Bioorg Med Chem; 2018 Jul; 26(12):3321-3344. PubMed ID: 29751989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.
    Li Y; Huang S; Huang X; Li X; Falcon A; Soutar A; Bornancin F; Jiang Z; Xin HB; Fu M
    Cell Signal; 2018 Oct; 50():1-8. PubMed ID: 29913212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
    Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
    J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of the
    Quancard J; Simic O; Pissot Soldermann C; Aichholz R; Blatter M; Renatus M; Erbel P; Melkko S; Endres R; Sorge M; Kieffer L; Wagner T; Beltz K; Mcsheehy P; Wartmann M; Régnier CH; Calzascia T; Radimerski T; Bigaud M; Weiss A; Bornancin F; Schlapbach A
    J Med Chem; 2020 Dec; 63(23):14594-14608. PubMed ID: 33216547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity.
    Unterreiner A; Touil R; Anastasi D; Dubois N; Niwa S; Calzascia T; Bornancin F
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30663686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinoline and thiazolopyridine allosteric inhibitors of MALT1.
    Scott DA; Hatcher JM; Liu H; Fu M; Du G; Fontán L; Us I; Casalena G; Qiao Q; Wu H; Melnick A; Gray NS
    Bioorg Med Chem Lett; 2019 Jul; 29(14):1694-1698. PubMed ID: 31129051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric activation of MALT1 by its ubiquitin-binding Ig3 domain.
    Schairer R; Hall G; Zhang M; Cowan R; Baravalle R; Muskett FW; Coombs PJ; Mpamhanga C; Hale LR; Saxty B; Iwaszkiewicz J; Décaillet C; Perroud M; Carr MD; Thome M
    Proc Natl Acad Sci U S A; 2020 Feb; 117(6):3093-3102. PubMed ID: 31980531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.